Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Cabaletta Bio, Inc.
Next earnings ≈ Aug 13, 2026 · est. from filing cadence
Last earnings +0.6% on 2026-05-14
Conservative balance sheet (liabilities/equity 0.47x).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Cabaletta Bio, Inc. shows limited reported revenue, and -149.8% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001759138, latest 10-Q filed 2026-05-14) · EODHD · rules-based read · as of 6/18/2026, 8:57:20 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$46.3M | -$54.1M | -$74.7M | -$125M | -$172M |
| Net income | -$46.3M | -$53.0M | -$67.7M | -$116M | -$168M |
| Diluted EPS | -$1.80 | -$1.81 | -$1.65 | -$2.34 | -$2.10 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median